STOCK TITAN

Medtronic plc (MDT) Stock News, Oct 1-29, 2026

MDT NYSE

Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.

Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.

Rhea-AI Summary

Orchestra BioMed (OBIO) will present its Virtue Sirolimus AngioInfusion Balloon and pivotal trial design at TCT on November 1, 2026.

The presentation will review drug delivery, preclinical and clinical evidence, and the actively enrolling Virtue Trial. This randomized U.S. trial plans approximately 740 patients and compares Virtue SAB with the AGENT paclitaxel-coated balloon for coronary in-stent restenosis, or renewed narrowing within a stent. In the earlier SABRE study, the three-year target lesion failure rate was 14.3% among all treated patients, with no additional repeat procedures at the treated lesion between years one and three.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary

Orchestra BioMed (OBIO) will host an R&D Day on November 12, 2026, focused on AVIM Therapy and Virtue SAB. The event begins at 3:00 p.m. ET in New York City and will be webcast live.

Company leaders and cardiologists will discuss uncontrolled hypertension in patients indicated for pacemakers, restenosis in coronary stent interventions, and the therapies’ potential to address these needs. Sessions will cover the BACKBEAT and Virtue pivotal trials, the Medtronic collaboration, upcoming clinical milestones and commercial potential. A replay will be available afterward on the company’s investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
-
Rhea-AI Summary

Medtronic (MDT) announced real-world registry results for its Sphere-9 catheter and PulseSelect pulsed field ablation system at APHRS 2026.

In 1,050 atrial fibrillation patients, the APEX analysis reported a 1.1% major complication rate. REAL PULSE, involving 1,160 atrial fibrillation patients, reported 100% acute success and a 0.09% acute major complication rate. A separate European APEX analysis of 46 ventricular tachycardia patients reported 87% acute success and estimated six-month freedom from recurrence of 75%. Six major complications occurred in four patients. Sphere-9 is CE marked for ventricular tachycardia but remains investigational and not approved for that use in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
Rhea-AI Summary

Medtronic (MDT) announced that its Stealth AXiS surgical system and the Corsano multi-parameter wearable were named TIME Best Inventions of 2026. TIME editors assess the annual list of new products and ideas.

Stealth AXiS combines surgical planning, navigation and robotic-assisted execution within Medtronic's AiBLE ecosystem, supporting spinal, cranial and ear, nose and throat procedures. The Corsano wearable captures vital signs and trending data for patient monitoring from hospital to home. It is manufactured by Corsano Health and distributed by Medtronic in the U.S. and Western Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE: MDT) has completed its separation of MiniMed Group, ending its remaining ownership through a share exchange offer. Medtronic elected to exchange all 252,813,348 MiniMed common shares it still held for outstanding Medtronic ordinary shares. The exchange offer was 5.4x subscribed. MiniMed trades under Nasdaq: MMED, and accepted tendering shareholders will receive MiniMed shares in book-entry form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
Rhea-AI Summary

MiniMed (MMED) completed its separation from Medtronic (MDT), marking its first day as a fully independent company.

Medtronic accepted 55,032,401 ordinary shares in exchange for 252,813,348 MiniMed common shares and no longer holds an equity stake in MiniMed. The exchange offer was 5.4x subscribed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Summary

Medtronic (MDT) announced final results of its oversubscribed exchange offer and elected to exchange its entire remaining MiniMed (MMED) stake.

Medtronic will exchange 252,813,348 MiniMed shares for 55,032,401 Medtronic ordinary shares. The final proration factor is 18.289133%, except for eligible odd-lot tenders. The offer expired October 9, 2026. After completion, Medtronic will hold no MiniMed common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
Rhea-AI Summary

Medtronic (MDT) announced preliminary results showing its MiniMed exchange offer was oversubscribed after expiring on October 9, 2026. Medtronic intends to accept 55,032,401 ordinary shares in exchange for its remaining 252,813,348 MiniMed shares, at 4.5939 MiniMed shares per accepted Medtronic share. Approximately 18.3% of tendered shares are estimated to be exchanged, subject to guaranteed deliveries. Medtronic expects the final proration factor on October 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.90%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE: MDT) set the final exchange ratio for its MiniMed split-off at 4.5939 MiniMed shares per accepted Medtronic share. The offer covers up to 225,361,295 MiniMed shares. If oversubscribed, Medtronic currently intends to exchange its remaining interest as well, adding 27,452,053 shares without extending the offer period. The offer and withdrawal rights expire at midnight, New York City time, at the end of October 9, 2026, unless extended or terminated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
none
Rhea-AI Summary

Medtronic (MDT) received American Medical Association approval for Category I procedure codes covering its Altaviva and Symplicity Spyral systems.

The permanent Current Procedural Terminology (CPT) codes replace existing Category III codes effective January 2028. Altaviva treats urge urinary incontinence and received FDA approval in September 2025 for patients who failed or could not tolerate more conservative treatments. Symplicity Spyral treats uncontrolled hypertension; its Medicare coverage was finalized in October 2025. Category I codes can support physician payment and inform commercial payer coverage decisions, but do not determine coverage, reimbursement, clinical superiority or patient access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none

FAQ

What is the current stock price of Medtronic (MDT)?

Medtronic (MDT) last closed at $102.88.

What is the market cap of Medtronic (MDT)?

The market cap of Medtronic (MDT) is approximately $131.6B.